{"prompt": "['1', 'MC1488', 'Mayo Clinic Cancer Center', 'MC1488: A Phase 2 study of WEE1 Inhibition with AZD1775 alone or combined with Cytarabine', 'in Patients with advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome', 'Study Chair:', 'Lisa Sproat, M.D.', 'Mayo Clinic', '5777 E. Mayo Blvd.', 'Phoenix, AZ 85054', '480/301-8000', 'IND Holder:', 'Study Co-Chairs:', 'Statistician:', 'Drug Availability', 'Supplied Investigational Agents: AZD1775', 'Commercial Agents: Cytarabine (cytosine arabinoside or AraC)', 'V', 'Study contributor(s) not responsible for patient care.', 'Document History', '(Effective Date)', 'Activation', 'May 5, 2017', 'MCCC Addendum #1', 'May 5,2017', 'MCCC Amendment #2', 'February 12, 2017']['2', 'AZD1775 in AML and MDS', 'Addendum #1', 'Protocol Resources', 'Questions:', 'Contact Name:', 'Patient eligibility*, test schedule,', 'Quality Assurance Specialist', 'treatment delays/interruptions/adjustments,', 'dose modifications, adverse events,', 'E-mail:', 'forms completion and submission', 'Drug administration, infusion pumps,', 'nursing guidelines', 'Pnone:', 'E-mail', 'Protocol document, consent form,', 'Research Protocol Specialist', 'regulatory issues', 'Email:', 'Adverse Events (AdEERS, MedWatch,', 'Non-AER, AML/MDS)', 'Pnone:', 'E-mail', '*No waivers per NCI']['3', 'AZD1775 in AML and MDS', 'Addendum #1', 'Index', 'Schema', '1.0', 'Background', '2.0', 'Goals', '3.0', 'Patient Eligibility', '4.0', 'Test Schedule', '5.0', 'Grouping and Stratification Factors', '6.0', 'Registration/Randomization Procedures', '7.0', 'Protocol Treatment', '8.0', 'Dosage Modification Based on Adverse Events', '9.0', 'Ancillary Treatment/Supportive Care/Concomitant Medications', '10.0', 'Adverse Event (AE) Reporting and Monitoring', '11.0', 'Treatment Evaluation Guideline', '12.0', 'Descriptive Factors', '13.0', 'Treatment/Follow-up Decision at Evaluation of Patient', '14.0', 'Body Fluid Biospecimens', '15.0', 'Drug Information', '16.0', 'Statistical Considerations and Methodology', '17.0', 'Pathology Considerations', '18.0', 'Records and Data Collection Procedures', '19.0', 'Budget Considerations', '20.0', 'References', 'Appendix I - ECOG Performance Status Scale', 'Appendix II - -Medication Diary', 'Appendix III - New York Heart Association Classification of Cardiac Disease', 'Appendix IV - Revised International Prognostic Scoring System (IPSS-R) for MDS', 'Appendix V - Risk Status Based on Validated Cytogenetics and Molecular Abnormalities', 'Appendix VI - List of prohibited concomitant medications and concomitant medications requiring caution', 'Appendix VII - Patient Information Sheet', 'Appendix VIII - EORTC QLQ-C30 & Myeloproliferative Neoplasm Symptom Assessment Form Total', 'Symptom Score (MPN-SAF TSS)', 'Appendix IX - Childbearing Potential & Contraception']\n\n###\n\n", "completion": "END"}